Bacteroides acidifaciens and its derived extracellular vesicles improve DSS-induced colitis
Frontiers in Microbiology · 30.11.2023 · 14
DOI: 10.3389/fmicb.2023.1304232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 30.11.2023. Verfasst von Cihua Zheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction “Probiotic therapy” to regulate gut microbiota and intervene in intestinal diseases such as inflammatory bowel disease (IBD) has become a research hotspot. Bacteroides acidifaciens , as a new generation of probiotics, has shown beneficial effects on various diseases.
Methods
In this study, we utilized a mouse colitis model induced by dextran sodium sulfate (DSS) to investigate how B. acidifaciens positively affects IBD. We evaluated the effects of B. acidifaciens , fecal microbiota transplantation, and bacterial extracellular vesicles (EVs) on DSS-induced colitis in mice. We monitored the phenotype of mouse colitis, detected serum inflammatory factors using ELISA, evaluated intestinal mucosal barrier function using Western blotting and tissue staining, evaluated gut microbiota using 16S rRNA sequencing, and analyzed differences in EVs protein composition derived from B. acidifaciens using proteomics to explore how B. acidifaciens has a positive impact on mouse colitis.
Results
We confirmed that B. acidifaciens has a protective effect on colitis, including alleviating the colitis phenotype, reducing inflammatory response, and improving intestinal barrier function, accompanied by an increase in the relative abundance of B. acidifaciens and Ruminococcus callidus but a decrease in the relative abundance of B. fragilis . Further fecal bacterial transplantation or fecal filtrate transplantation confirmed the protective effect of eosinophil-regulated gut microbiota and metabolites on DSS-induced colitis. Finally, we validated that EVs derived from B. acidifaciens contain rich functional proteins that can contribute to the relief of colitis.
Conclusion
Therefore, B. acidifaciens and its derived EVs can alleviate DSS-induced colitis by reducing mucosal damage to colon tissue, reducing inflammatory response, promoting mucosal barrier repair, restoring gut microbiota diversity, and restoring gut microbiota balance in mice. The results of this study provide a theoretical basis for the preclinical application of the new generation of probiotics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
- Department of Rehabilitation Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
- The Institute of Translational Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
- Graduate School of Jiangxi University of Chinese Medicine, Nanchang, China.
Zitieren
APA
Zheng, C., Zhong, Y., Xie, J., Wang, Z., Zhang, W., Pi, Y., Zhang, W., Liu, L., Luo, J., & Xu, W. (2023). Bacteroides acidifaciens and its derived extracellular vesicles improve DSS-induced colitis. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1304232
Vancouver
Zheng C, Zhong Y, Xie J, Wang Z, Zhang W, Pi Y, et al. Bacteroides acidifaciens and its derived extracellular vesicles improve DSS-induced colitis. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1304232
BibTeX
@article{Zheng2023,
author = {Zheng, Cihua and Zhong, Yuchun and Xie, Jian and Wang, Zhuoya and Zhang, Wenming and Pi, Yiming and Zhang, Wenjun and Liu, Li and Luo, Jun and Xu, Wei},
title = {Bacteroides acidifaciens and its derived extracellular vesicles improve DSS-induced colitis},
journal = {Frontiers in Microbiology},
year = {2023},
volume = {14},
doi = {10.3389/fmicb.2023.1304232}
}
EUVIMED